VHL phenotype classification (Type 1 / 2A / 2B / 2C)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-VHL-CLASSIFICATION-PHENOTYPE |
|---|---|
| Type | Biomarker |
| Aliases | VHL Type 1VHL Type 2AVHL Type 2BVHL Type 2CVHL phenotype stratificationVHL phenotype subtype classificationКласифікація фенотипу VHL (Тип 1 / 2A / 2B / 2C) |
| Status | reviewed 2026-05-18 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-KIDNEY-2025 SRC-NCCN-NET-2025 |
Biomarker Facts
| Biomarker type | composite_score |
|---|---|
| Mutation details | {"functional_impact": "loss_of_function (partial vs complete)", "gene": "VHL", "gene_hugo_id": "HGNC:12687", "variant_type": "missense / truncating / large deletion (variant class predicts phenotype)"} |
| Related biomarkers | BIO-VHL-GERMLINE |
Notes
Composite genotype-phenotype classification for von Hippel-Lindau syndrome (germline VHL pathogenic variant carriers). Four canonical subtypes based on pheochromocytoma risk and variant class: • Type 1: complete-loss-of-function variants (truncating, large deletions, missense disrupting elongin-binding) — RCC + CNS/retinal hemangioblastomas + pancreatic NET/cysts WITHOUT pheochromocytoma (or very low pheo risk). • Type 2A: specific missense variants (e.g., Tyr98His) — pheo + CNS/ retinal hemangioblastomas, LOW RCC risk. • Type 2B: missense variants (e.g., Arg167Trp / Arg167Gln) — pheo + RCC + CNS/retinal hemangioblastomas (full classical VHL spectrum). • Type 2C: rare missense variants (e.g., Leu188Val) — pheochromocytoma ONLY (no RCC, no hemangioblastomas). Surveillance intensity follows phenotype: ALL types get annual ophthalmologic exam + brain/spine MRI; Type 1 + 2B get annual abdominal MRI; Type 2A/2B/2C get annual plasma metanephrines (see BIO-METANEPHRINES-PLASMA-PHEO). Belzutifan (HIF-2α inhibitor) approved for VHL-associated RCC, hemangioblastoma, pNET in adults with non- immediately-resectable disease. Classification guides discussion with patient/family but does NOT red...
Used By
Biomarker
BIO-METANEPHRINES-PLASMA-PHEO- Plasma free metanephrines (pheochromocytoma/paraganglioma surveillance — VHL/MEN2/SDH)